Myo-inositol was reported to lower serum lipid levels and reduce the risk of fatty liver, and inositol synthesis may contribute to NAFLD [45]; therefore, the increase in inositol-3-phosphate synthase 1 (ISYNA1), involved in inositol synthesis, could potentially play a role in the TUG-891-dependent inhibition of liver steatosis. Here, ISYNA1 is linked to metabolic dysfunction-associated steatotic liver disease.